Wellington Shields & Co. LLC grew its stake in Juno Therapeutics Inc (NASDAQ:JUNO) by 37.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,200 shares of the biopharmaceutical company’s stock after purchasing an additional 1,700 shares during the period. Wellington Shields & Co. LLC’s holdings in Juno Therapeutics were worth $283,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in JUNO. The Manufacturers Life Insurance Company increased its holdings in shares of Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 228 shares during the period. Advisor Group Inc. grew its holdings in Juno Therapeutics by 141.1% during the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,439 shares during the period. QS Investors LLC acquired a new position in Juno Therapeutics during the second quarter worth $135,000. Bronfman E.L. Rothschild L.P. grew its holdings in Juno Therapeutics by 27,376.9% during the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 3,559 shares during the period. Finally, State of Alaska Department of Revenue acquired a new position in Juno Therapeutics during the fourth quarter worth $173,000. 69.13% of the stock is currently owned by institutional investors and hedge funds.

Shares of Juno Therapeutics Inc (NASDAQ JUNO) opened at $85.90 on Thursday. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $9,859.70, a price-to-earnings ratio of -25.41 and a beta of 3.43. Juno Therapeutics Inc has a 12-month low of $19.62 and a 12-month high of $86.28.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.07. The company had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. Juno Therapeutics’s quarterly revenue was up 115.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.57) earnings per share. equities analysts predict that Juno Therapeutics Inc will post -4.02 EPS for the current year.

In other news, EVP Robert Azelby sold 4,167 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $85.78, for a total value of $357,445.26. Following the sale, the executive vice president now directly owns 96,471 shares in the company, valued at $8,275,282.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard Klausner sold 12,724 shares of the company’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $48.21, for a total value of $613,424.04. Following the completion of the sale, the director now owns 741,499 shares in the company, valued at $35,747,666.79. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 465,377 shares of company stock worth $26,375,636. 15.08% of the stock is owned by company insiders.

JUNO has been the topic of a number of recent analyst reports. Cowen reaffirmed a “buy” rating and set a $49.00 price objective on shares of Juno Therapeutics in a report on Friday, October 27th. Citigroup reaffirmed a “buy” rating and set a $59.00 price objective on shares of Juno Therapeutics in a report on Tuesday, October 31st. SunTrust Banks raised Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 2nd. Wedbush reaffirmed an “outperform” rating and set a $64.00 price objective (up previously from $42.00) on shares of Juno Therapeutics in a report on Thursday, November 2nd. Finally, Leerink Swann reaffirmed an “in-line” rating and set a $56.00 price objective (up previously from $34.00) on shares of Juno Therapeutics in a report on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $51.20.

ILLEGAL ACTIVITY WARNING: This story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2018/02/08/wellington-shields-co-llc-buys-1700-shares-of-juno-therapeutics-inc-juno.html.

Juno Therapeutics Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics Inc (NASDAQ:JUNO).

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.